These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 20232119)
1. Formulation development and in vivo evaluation of a new dry powder formulation of albuterol sulphate in beagle dogs. Kuehl PJ; Barrett EG; McDonald JD; Rudolph K; Vodak D; Dobry D; Lyon D Pharm Res; 2010 May; 27(5):894-904. PubMed ID: 20232119 [TBL] [Abstract][Full Text] [Related]
2. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Son YJ; Worth Longest P; Hindle M Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343 [TBL] [Abstract][Full Text] [Related]
3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers. Zeng XM; MacRitchie HB; Marriott C; Martin GP Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863 [TBL] [Abstract][Full Text] [Related]
4. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate. Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688 [TBL] [Abstract][Full Text] [Related]
5. The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. Srichana T; Suedee R; Muanpanarai D; Tanmanee N J Pharm Sci; 2005 Jan; 94(1):220-30. PubMed ID: 15761945 [TBL] [Abstract][Full Text] [Related]
6. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations. Martin GP; Marriott C; Zeng XM Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114 [TBL] [Abstract][Full Text] [Related]
7. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301 [TBL] [Abstract][Full Text] [Related]
8. The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems. Hoe S; Traini D; Chan HK; Young PM Pharm Res; 2010 Jul; 27(7):1325-36. PubMed ID: 20354768 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. Waldrep JC; Berlinski A; Dhand R J Aerosol Med; 2007; 20(3):310-9. PubMed ID: 17894537 [TBL] [Abstract][Full Text] [Related]
10. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246 [TBL] [Abstract][Full Text] [Related]
11. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Corrigan DO; Corrigan OI; Healy AM Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654 [TBL] [Abstract][Full Text] [Related]
12. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations. Marriott C; MacRitchie HB; Zeng XM; Martin GP Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848 [TBL] [Abstract][Full Text] [Related]
13. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate. Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711 [TBL] [Abstract][Full Text] [Related]
14. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method. Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548 [TBL] [Abstract][Full Text] [Related]
15. The role of force control agents in high-dose dry powder inhaler formulations. Begat P; Morton DA; Shur J; Kippax P; Staniforth JN; Price R J Pharm Sci; 2009 Aug; 98(8):2770-83. PubMed ID: 19067395 [TBL] [Abstract][Full Text] [Related]
16. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices. Ooi J; Gill C; Young PM; Traini D Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438 [TBL] [Abstract][Full Text] [Related]
17. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation. Chege JK; Chrystyn H Respir Med; 2000 Jan; 94(1):51-6. PubMed ID: 10714479 [TBL] [Abstract][Full Text] [Related]
18. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers. Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906 [TBL] [Abstract][Full Text] [Related]
19. Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers. Jetmalani K; Young PM; Smith T; Stewart P; Traini D Drug Dev Ind Pharm; 2012 Dec; 38(12):1504-11. PubMed ID: 22335558 [TBL] [Abstract][Full Text] [Related]
20. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Srichana T; Martin GP; Marriott C Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]